Table 6.
Renal outcomes based on categorical grouping of TA-P and TA-MAP excretion during follow-up based on univariate and multivariate Cox regression analyses.
| Items | Renal survival from ESRD | Renal survival from ESRD or a 50% decline in renal function | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate (HR, 95% CI) | P | Multivariate(HR, 95% CI)# | P | Univariate (HR, 95% CI) | P | Multivariate (HR, 95% CI)# | P | |
| TA-P | ||||||||
| <1.0 g/day | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| >1.0 g/day | 95.426 (22.779–399.764) | P < 0.001** | 59.689 (13.947–255.458) | P < 0.001** | 28.926 (14.347–58.320) | P < 0.001** | 19.926 (9.559–41.534) | P < 0.001** |
| TA-P | ||||||||
| <0.4 g/day | 1.0 | 1.0 | 1.0 | 1.0 | ||||
| 0.4–1.0 g/day | 1.892 (0.171–20.865) | P = 0.603 | 1.766 (0.161–19.613) | P = 0.639 | 3.803 (1.057–13.683) | P = 0.041* | 3.715 (1.031–13.391) | P = 0.045* |
| >1.0 g/day | 90.347 (12.295–633.909) | P < 0.001** | 53.791 (7.173–403.416) | P < 0.001** | 62.624 (18.353–213.682) | P < 0.001** | 42.629 (12.176–149.244) | P < 0.001** |
#Multivariate Cox model: multivariate with TA-P, TA-MAP, baseline hypertension, baseline proteinuria and an eGFR <60 mL/min/1.73 m2 at biopsy.
ESRD end-stage renal disease; HR hazard ratio; CI confidence interval; TA-P time-average proteinuria.
*P < 0.05, **P < 0.01.